Test Strip - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Test strip market size in 2026 is estimated at USD 17.29 billion, growing from 2025 value of USD 16.69 billion with 2031 projections showing USD 20.66 billion, growing at 3.63% CAGR over 2026-2031. This report is Segmented by Product (Blood Test Strips and Urine Test Strips), Application (Diabetes, Pregnancy Detection, Urinary Tract Infection, and More), End User (Hospitals & Clinics, Homecare / Personal Use, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Test Strip Market Trends and Insights

Surging Global Diabetes Prevalence

International Diabetes Federation models indicate that 783.2 million adults will have diabetes by 2045, up 46% from 2021 numbers. This epidemiological swell secures a large addressable base for self-monitoring tools. While higher caseloads support the test strip market, CGM uptake in high-income countries tempers per-patient strip volumes, with German data showing 40% usage declines post CGM initiation. This cannibalization effect suggests that while diabetes prevalence drives overall market expansion, the per-patient consumption of traditional test strips may decline in developed markets with high CGM penetration.

Preference Shift to Point-Of-Care Diagnostics

Point-of-care (POC) testing is growing annually, reinforcing healthcare moves toward decentralized, rapid results. FDA clearance of a hepatitis C RNA POC test and expanding EHR integrations, such as Abbott’s Epic linkage, strengthen clinical confidence in strip-based assays. The trend particularly benefits urine test strips for UTI screening, where 20 commercially available POC tests now provide results within hours compared to traditional 24-48 hour culture methods.

Sparse Reimbursement for OTC Strip Purchases

Coverage gaps limit retail uptake, particularly among non-insulin users who receive only 100 strips per quarter under United States Medicare guidelines. Emerging economies face heavier out-of-pocket burdens, prompting domestic innovators like Morepen Labs to push low-priced meters for India’s potential 100 million diabetic population. The reimbursement gap particularly affects continuous monitoring adoption, where CGM devices receive coverage while traditional strips face increasing restrictions, creating a bifurcated market where insured patients migrate to CGM while uninsured populations rely on cost-constrained traditional testing.

Other drivers and restraints analyzed in the detailed report include:

• Continuous Technology Upgrades in Enzymatic Chemistries
• Smartphone-Enabled Optical Strip Readers Gain Regulatory Green-Lights
• CGM Uptake Cannibalising Glucose-Strip Volumes

Segment Analysis

Blood glucose strips generated 70.92% of 2025 revenue for the test strip market, anchored by entrenched therapeutic guidelines and insurance coverage. The segment benefits from enzymatic refinements that enable 0.5 microliter samples and 7-second reads, showcased by ARKRAY’s GLUCOCARD Vital platform. Yet, urine panels are expanding at a 4.89% CAGR as healthcare providers promote early screening for urinary tract infections, kidney disease, and pregnancy. ARKRAY’s 11-parameter AUTION line illustrates the multi-analyte advantage, encouraging physicians to replace single-purpose strips with comprehensive urinalysis.

Growth momentum in urine diagnostics hinges on preventive medicine trends. Digital telehealth platforms in urban China integrate home urine strips with cloud analytics, enabling remote physician oversight and medication adherence tracking. Blood-strip makers counter by embedding Bluetooth and EHR connectivity to preserve relevance.

Diabetes care produced 65.31% of 2025 revenue for the test strip market, yet its growth is moderating to 2.96% annually as CGM substitution accelerates in high-income markets. Conversely, urinary tract infection screening is accelerating at 4.48% CAGR, supported by primary-care protocols that favor rapid POC urinalysis to curb antibiotic misuse. Pregnancy testing maintains steady demand, aided by dual fertility functions and smartphone readers that improve result interpretation.

Clinical guidelines recommending quarterly HbA1c POC tests extend strip-based HbA1c opportunities in both urban and rural China, where cost-utility ratios fall well below local GDP per capita thresholds. The test strip industry also witnesses crossover innovation. Researchers adapted glucometers to quantify SARS-CoV-2 antibodies, proving the platform’s flexibility for future multiplex infectious disease panels.

Complete Report Scope:

• By Product
  • Blood Test Strips
  • Urine Test Strips
• By Application
  • Diabetes
  • Pregnancy Detection
  • Urinary Tract Infection
  • Other Applications
• By End User
  • Hospitals & Clinics
  • Homecare / Personal Use
  • Diagnostic Laboratories
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 37.72% of 2025 revenue for the test strip market, enabled by well-established insurance coverage and widespread chronic disease management programs. Medicare’s 300-strip quarterly limit for insulin users ensures baseline demand, and the 2024 USD 35 insulin copay cap frees consumer cash for ancillary supplies. Yet, CGM expansion moderates volume growth as Abbott and Medtronic push OTC sensors to retail shelves. Federal Laboratory Developed Test policy changes introduce predictable compliance pathways, encouraging multinational entrants to sustain investment.

Asia-Pacific delivers the fastest regional CAGR at 5.12%, driven by climbing diabetes prevalence, urban dietary shifts, and expanding middle-class purchasing power. China’s integrated digital management initiatives cut average fasting glucose by 1.68 mmol/L in Tianjin pilots, underscoring demand for connected home testing. India’s domestic manufacturing scale-up from 2.5 million to 5 million glucometers annually lifts supply resilience, while lower per-capita income keeps price elasticity high. Point-of-care HbA1c screening in rural China also proves cost-effective, demonstrating the appeal of compact strip readers in resource-constrained settings.

Europe sustains moderate expansion under the In Vitro Diagnostic Regulation transitional timelines to 2027-2029, which maintain device availability during recertification. Partnership-led growth emerges as A. Menarini secures exclusive Sinocare CGM rights across more than 20 jurisdictions, blending continuous and strip-based portfolios. Meanwhile, Middle East, Africa, and South America represent nascent demand pools where limited reimbursement favors low-priced strips over premium CGM hardware.

List of Companies Covered in this Report:

• Abbott Laboratories
• Acon Laboratories
• Ascensia
• Arkray
• B. Braun
• Lifescan
• Roche
• Siemens Healthineers
• TaiDoc
• Trividia Health
• Nova Biomedical
• Danaher
• Medtronic
• Beckton Dickinson
• Orasure Technologies
• QuidelOrtho
• CoaguSense

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support